Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Abivax SA Sponsored ADR (ABVX) have performed compared to their sector so far this year.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
EMEA Expansion to Support BSX Stock Amid Fierce Competition
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
What's Behind The 130% Rise In BSX Stock?
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ahead of the earnings announcement.
Best Momentum Stocks to Buy for February 10th
BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.
New Strong Buy Stocks for February 10th
PFIS, BSX, ENVA, NFG and NLY have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2025.
Boston Scientific (BSX) is a Great Momentum Stock: Should You Buy?
Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Alphatec (ATEC) have performed compared to their sector so far this year.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Frederick Wise - Stifel Joanne Wuensch - Citibank David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Joshua Jennings - TD Cowen Chris Pasquale - Nephron Research Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. All participants will be listen-only mode.
Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin
Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.
